JHS Sven.Lab.

- There is no explicit mention of any current or future fundraising through debt or equity during the call. - The company plans to pursue acquisitions in the current financial year using available cash and possibly some stock. - Nikhil Nanda mentioned acquiring facilities and growing inorganically but did not specify raising additional funds through debt or equity. - The company has improved its operational efficiency and credit period management, indicating focus on internal resource optimization. - No announcements on fresh capital raising or fundraising plans were discussed in the Q4 and FY24 earnings conference call.

- No major new capex planned except for specific new moulds for customers, which constitute about 5% to 8% of the overall capex for production lines. - Existing production capacity is around 30-35% utilization, targeted to ramp up to 70-80% in the next two years without significant new capex. - Some capex is required for new product categories beyond oral care, primarily for packaging lines due to varying packaging needs (pouches, bottles, pumps). - The company is actively looking at acquisitions (not mergers) and is confident of undertaking a substantial acquisition in the current financial year using existing cash and possibly stock. - No new merger plans currently after the Vedic merger did not materialize, with focus shifted to acquisitions instead.

- JHS Svendgaard expects a 30% to 40% increase in revenue for FY25 compared to FY23-24. - Growth to be driven by both organic expansion (new customers like Unilever, Amway, Reliance, Zydus) and inorganic acquisitions in broader personal care segments. - Capacity utilization targeted to increase from current 30-35% to 70-80% over the next two years without major new capex except for customer-specific moulds. - Increased sales volumes anticipated especially as Reliance's general trade oral care business ramps up. - Export sales, which dropped during COVID to 1-2% of sales, are recovering with improved terms and margins. - Management confident about consistent quarter-on-quarter growth in sales, revenue, and profitability in coming years. - Emphasis on maintaining customer diversification with none exceeding 25% of revenue, reducing dependency risks.

- The company expects consistent quarter-on-quarter growth in revenue and profitability over the coming years driven by both organic and inorganic means. - FY25 revenue is projected to increase by 30%-40% over FY24. - EBITDA margins are expected to improve to healthy mid-teen double digits driven by operational efficiencies, price revisions, and optimized raw material costs. - Increased sales volumes are anticipated to bring economies of scale, aiding margin expansion. - The company has a firm order book of approximately INR 110 crores for the current financial year with expectations to improve further. - Efforts to add new clients, increase capacity utilization from 30%-35% to around 70%-80% in the next two years will support growth. - Acquisition plans in the personal care segment aim to supplement growth and profitability. - Profitability is targeted to show noticeable improvement starting from Q1 of the current financial year.

- The current firm order book for JHS Svendgaard Laboratories Limited stands at approximately INR 110 crores for the financial year 2024-25. - The company expects to start executing these orders from Q1 of the current financial year. - Management expressed confidence in improving this order book size in the coming months. - There is a clear focus on ramping up capacity utilization from the current 30-35% to about 70-80% over the next two years, which would support higher order execution without major new capex. - New customers like Reliance, Amway, and Unilever have been added, contributing to the order book expansion. - The company is actively pursuing acquisitions to strengthen growth and order inflows further.